Litcius/Paper detail

Factors associated with ocular adverse event after immune checkpoint inhibitor treatment

Yong Joon Kim, Jihei Sara Lee, Junwon Lee, Sung Chul Lee, Tae‐im Kim, Suk Ho Byeon, Christopher Seungkyu Lee

2020Cancer Immunology Immunotherapy25 citationsDOIOpen Access PDF

Topics & Concepts

MedicineNivolumabDurvalumabTremelimumabPembrolizumabIpilimumabAdverse effectInternal medicineSurgeryDermatologyCancerImmunotherapyCancer Immunotherapy and BiomarkersMelanoma and MAPK PathwaysBrain Metastases and Treatment
Factors associated with ocular adverse event after immune checkpoint inhibitor treatment | Litcius